HMTXF headed up after the new cost cutting agreeme

HMTXF headed up after the new cost cutting agreement!
Hemostemix Licenses CytoImmunes BioReactor Technologies
3:24 PM ET 2/19/25 | Dow Jones

Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company" is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect its autologous stem cell market, and create a cost-effective allogenic stem cell expansion strategy.

Subject to the TSXV Exchange acceptance, Hemostemix will pay CytoImmune $5,000,000 (twenty million shares) for a perpetual, global, royalty free license.

Hemostemix's Strategic Advantages from CytoImmune's Bioreactor Technologies License
-- Lowest cost of goods sold for allogenic products.

-- Strategic fence around autologous stem cell production.

-- Scalability and commercial-ability of ACP-01 behind the fence.

Lowest Cost of Goods Sold (COGS) in the Industry

One of the most significant benefits of integrating CytoImmune's Bioreactor technologies into Hemostemix's allogenic stem cell manufacturing processes is the dramatic reduction in the cost of goods sold. Traditional stem cell expansion methods are expensive, labor-intensive, and often reliant on inefficient batch-of-one processing. The key advantages of bioreactor technology include:
-- Automated Cell Expansion: Continuous and scalable production reduces
manual labor and batch-to-batch variability, ensuring consistent,
high-quality stem cell output.

-- High Yield & Efficiency: The bioreactor platform maximizes cell
proliferation rates, producing exponentially more therapeutic doses per
donor-derived stem cell input.

-- Reduced Facility and Labor Costs: The efficiency of automated bioreactor
systems minimizes the need for extensive cleanroom environments and
skilled labor, leading to significant cost reductions.

-- Economies of Scale: Mass production becomes feasible at a fraction of the
cost of traditional autologous methods.

Building an Allogenic Stem Cell Fence Around Hemostemix's Autologous Market

By leveraging CytoImmune's Bioreactor technologies, Hemostemix secures an allogenic supply of stem cells that strategically complements its autologous offering. This creates a "stem cell fence"--a protective market barrier that prevents competitors from encroaching on Hemostemix's territory.